NCT04130516 2025-12-18Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabLinnaeus Therapeutics, Inc.Phase 1/2 Recruiting200 enrolled
NCT06784648 2025-11-19Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaBioInvent International ABPhase 1/2 Active not recruiting35 enrolled